Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387281 | 0.83 | FAAH (0.51) | HRH3ALDH1A1TSHRTAAR1PKM | |
| SCHEMBL5041999 | 0.77 | ALDH1A1 (0.53) | ALDH1A1TSHRHDAC3HDAC6 | |
| SCHEMBL5040593 | 0.74 | SRC (0.46) | ALDH1A1TSHRTDP1LMNAESR1 | |
| SCHEMBL28194345 | 0.74 | CYP2C9 (0.46) | ALDH1A1CYP2C9 | |
| SCHEMBL29069338 | 0.74 | KEAP1 (0.41) | ALDH1A1TSHRPKMLMNAPTGS1 | |
| SCHEMBL24327745 | 0.74 | KEAP1 (0.55) | ALDH1A1PKMTDP1LMNAALOX5 | |
| SCHEMBL104518 | 0.74 | ALDH1A1 (0.54) | ALDH1A1PKMLMNA | |
| SCHEMBL155984 | 0.74 | ALDH1A1 (0.54) | ALDH1A1PKMLMNA | |
| SCHEMBL103235 | 0.74 | ALDH1A1 (0.54) | ALDH1A1PKMLMNA | |
| SCHEMBL24327729 | 0.73 | KDM4E (0.46) | ALDH1A1HDAC3HDAC6LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| CN-104710385-B | PDE10 inhibitor and compositions related and method | 奥默罗斯公司 | 2018-11-09 | — | — | CN | disclosed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| CN-107445919-A | PDE10 inhibitor and compositions related and method | 奥默罗斯公司 | 2017-12-08 | — | — | CN | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2544679-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | Omeros Corporation (US) | 2013-01-16 | — | — | EP | disclosed |
| CN-102869355-A | Pde10 inhibitors and related compositions and methods | OMEROS CORP | 2013-01-09 | — | — | CN | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343970-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011112828-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112828-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | HRH3 2767/4885ALDH1A1 2053/4885TSHR 2134/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | HRH3 2767/4885ALDH1A1 2053/4885TSHR 2134/4885 |
| US-20110224202-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | HRH3 2767/4885ALDH1A1 2053/4885TSHR 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.